Elshaer Amani, Chascsa David M H, Lizaola-Mayo Blanca C
Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ 85054, USA.
Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, AZ 85054, USA.
Life (Basel). 2024 Jul 3;14(7):844. doi: 10.3390/life14070844.
Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a liver disorder characterized by steatosis with underlying metabolic risk factors. The prevalence of MASLD continues to rise, leading to increased patient risk of various complications. Recent research has been focused on new therapeutic strategies to reduce the incidence of MASLD and provide effective treatment plans to prevent further irreversible liver damage. The treatment approach is multifactorial, with a primary focus on weight loss and management of underlying comorbidities through lifestyle modifications, pharmacotherapy, or surgical options. Ongoing research is exploring new pharmacological therapies that could enhance the treatment of MASLD.
代谢功能障碍相关脂肪性肝病(MASLD)是一种以脂肪变性为特征且伴有潜在代谢风险因素的肝脏疾病。MASLD的患病率持续上升,导致患者出现各种并发症的风险增加。最近的研究集中在新的治疗策略上,以降低MASLD的发病率,并提供有效的治疗方案来预防进一步的不可逆肝损伤。治疗方法是多方面的,主要侧重于通过生活方式改变、药物治疗或手术选择来减轻体重和管理潜在的合并症。正在进行的研究正在探索可增强MASLD治疗效果的新药理学疗法。